

Supplemental Figure 1. PD-L1 expression was determined by Western blot analysis in the EL4 and B16F10 murine cell lines, with and without IFN-γ (**A**). Expression was quantified and normalized to β-actin [PD-L1/β-actin], with and without IFN-γ (**B**).



Supplemental Figure 2. PD-L1 expression in selected organs of a non–tumor-bearing C57BL/6 mouse was determined by Western blot analysis with B16F10 cells serving as a positive control (**A**). Expression was quantified and normalized to β-actin [PD-L1/β-actin] and set as a ratio to expression in B16F10 cells (**B**).



Supplemental Figure 3. Binding assays performed with ^{111}In-DTPA-anti-PD-L1-BC using B16F10 cells treated with IFN-γ (400 ng/mL). (**A**) Total [red] and nonspecific [blue] binding. (**B**) Specific binding [purple].



Supplemental Figure 4. A coronal and sagittal slice of a whole-body SPECT image of ^{111}In-DTPA-anti-PD-L1-BC 24 hrs after injection in a prone C57BL/6 mouse bearing a B16F10 tumor. Signal from the thymus is highlighted by the red cross arrows.



Supplemental Figure 5. A coronal and sagittal slice of a whole-body SPECT image of ^{111}In-DTPA-anti-PD-L1-BC 24 hrs after injection in a prone C57BL/6 mouse bearing a B16F10 tumor. Signal from the BAT is highlighted by the red cross arrows.



Supplemental Figure 6. A coronal (A), transverse (B), and sagittal (C) slice of a whole-body SPECT image of ^{111}In-DTPA-anti-PD-L1-BC 72 hrs after injection in a prone C57BL/6 mouse bearing a B16F10 tumor. Voxel intensity (Mbq/ml) was calibrated from a SPECT image of a known activity and volume.